Response to Pegylated Interferon in a COVID-19 Positive Male with
Metastatic Jejunal Neuroendocrine Tumor Treated with Everolimus
- Arthur Frankel
, - Wai Yip,
- Eknath Naik,
- Hans Hasselbalch
Abstract
A 61 years old male had minimally symptomatic SARS-CoV-2 infection while
taking everolimus. He remained RT-PCR positive for viral RNA for 52
days. Pegylated interferon for 4 weeks led to viral RNA clearance. The
observations support consideration and further evaluation of combination
therapy with everolimus plus interferon for COVID-19.08 Feb 2021Submitted to Clinical Case Reports 09 Feb 2021Submission Checks Completed
09 Feb 2021Assigned to Editor
18 Feb 2021Reviewer(s) Assigned
29 Mar 2021Review(s) Completed, Editorial Evaluation Pending
31 Mar 2021Editorial Decision: Revise Minor
31 Mar 20211st Revision Received
01 Apr 2021Submission Checks Completed
01 Apr 2021Assigned to Editor
01 Apr 2021Review(s) Completed, Editorial Evaluation Pending
11 Apr 2021Editorial Decision: Accept
